Published by Coherent Market Insights
Posted on September 16, 2021
6 min readLast updated: January 20, 2026
Nasal Lacrimal Stent Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of FCI Ophthalmics, Kaneka Corporation, Cook Medical LLC., and Sinopsys Surgical, Inc.
Nasal lacrimal stent is used in the treatment of trauma, infection, malignancy, thermal injury, chemotherapy, radiation, and iatrogenic causes. Increasing cases of trauma are expected to aid in growth of the nasal lacrimal stent market. According to January 2018 factsheet of the World Health Organization, 20–30% of older people who fall suffer moderate to severe injuries such as bruises, hip fractures, or head trauma, in the U.S. Increasing geriatric population is also expected to aid in growth of the market. According to United Nations Population Fund, geriatric population in Asia Pacific is expected to triple between 2010 and 2050 to reach 1.3 billion people by 2050.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/3183
In the nasal lacrimal stent market, nasal lacrimal stents are typically classified into bicanalicular stents and monocanalicular stents. Bicanalicular stents can be further divided into Crawford stent, Ritleng Stent, Pigtail/Donut stent, and Kaneka Lacriflow stent and monocanalicular stents can be further divided into Monoka Stent and Jones Tube.
Nasal lacrimal stents can be used in the treatment of epiphora, an overflow of tears onto the face, other than caused by normal crying. The prevalence of postoperative epiphora was 3.6% and it persisted for a mean of 32.7 days, as per the study ‘Prevalence of nasolacrimal canal obstruction and epiphora following maxillary orthognathic surgery’ published in 2018. Thus, high prevalence of epiphora is expected to aid in growth of the nasal lacrimal stent market.
High prevalence of canalicular obstruction is also expected to aid in growth of the nasal lacrimal stent market. Nasal lacrimal stents also play a major role in the management of idiopathic distal canalicular obstructions. Congenital nasolacrimal duct obstruction is a common condition causing excessive tearing or mucoid discharge from the eyes, due to blockage of the nasolacrimal duct system. The frequency of canalicular obstruction has been reported to be between 16 and 25% in patients presenting with obstructive epiphora.
Placement of nasolacrimal stents can result in some complications, which is expected to limit growth of the nasal lacrimal stent market. The complications include, prolapse of the stent, damage to the puncta, granuloma formation, trauma to the canalicular system with creation of a false passage, and infection of the nasolacrimal drainage system. Moreover, the success rate of the nasolacrimal stent decreases as follow-up lengthens, which also limits their adoption.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/3183
Reasons to Purchase this Report
• Current and future of global Nasal Lacrimal Stent Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Nasal Lacrimal Stent Market Global Analysis, Growth Rate, Modern Trend, Demographical Dynamics and Analysis of Key Strategies By 2027 appeared first on Gatorledger.
Nasal Lacrimal Stent Market – Competitive Landscape
Key players functioning in the global prosthetic liners market consists of FCI Ophthalmics, Kaneka Corporation, Cook Medical LLC., and Sinopsys Surgical, Inc.
Nasal lacrimal stent is used in the treatment of trauma, infection, malignancy, thermal injury, chemotherapy, radiation, and iatrogenic causes. Increasing cases of trauma are expected to aid in growth of the nasal lacrimal stent market. According to January 2018 factsheet of the World Health Organization, 20–30% of older people who fall suffer moderate to severe injuries such as bruises, hip fractures, or head trauma, in the U.S. Increasing geriatric population is also expected to aid in growth of the market. According to United Nations Population Fund, geriatric population in Asia Pacific is expected to triple between 2010 and 2050 to reach 1.3 billion people by 2050.
Request Here For Market Latest Insights: https://www.coherentmarketinsights.com/insight/request-pdf/3183
In the nasal lacrimal stent market, nasal lacrimal stents are typically classified into bicanalicular stents and monocanalicular stents. Bicanalicular stents can be further divided into Crawford stent, Ritleng Stent, Pigtail/Donut stent, and Kaneka Lacriflow stent and monocanalicular stents can be further divided into Monoka Stent and Jones Tube.
Nasal lacrimal stents can be used in the treatment of epiphora, an overflow of tears onto the face, other than caused by normal crying. The prevalence of postoperative epiphora was 3.6% and it persisted for a mean of 32.7 days, as per the study ‘Prevalence of nasolacrimal canal obstruction and epiphora following maxillary orthognathic surgery’ published in 2018. Thus, high prevalence of epiphora is expected to aid in growth of the nasal lacrimal stent market.
High prevalence of canalicular obstruction is also expected to aid in growth of the nasal lacrimal stent market. Nasal lacrimal stents also play a major role in the management of idiopathic distal canalicular obstructions. Congenital nasolacrimal duct obstruction is a common condition causing excessive tearing or mucoid discharge from the eyes, due to blockage of the nasolacrimal duct system. The frequency of canalicular obstruction has been reported to be between 16 and 25% in patients presenting with obstructive epiphora.
Placement of nasolacrimal stents can result in some complications, which is expected to limit growth of the nasal lacrimal stent market. The complications include, prolapse of the stent, damage to the puncta, granuloma formation, trauma to the canalicular system with creation of a false passage, and infection of the nasolacrimal drainage system. Moreover, the success rate of the nasolacrimal stent decreases as follow-up lengthens, which also limits their adoption.
Purchase this Report at Discount Of US $2000 Flat OFF – https://www.coherentmarketinsights.com/promo/buynow/3183
Reasons to Purchase this Report
• Current and future of global Nasal Lacrimal Stent Market outlook in the developed and emerging markets • The segment that is expected to dominate the market as well as the segment which holds highest CAGR in the forecast period. • Regions/countries that are expected to witness the fastest growth rates during the forecast period • The latest developments, market shares, and strategies that are employed by the major market players
Contact Us
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837
The post Nasal Lacrimal Stent Market Global Analysis, Growth Rate, Modern Trend, Demographical Dynamics and Analysis of Key Strategies By 2027 appeared first on Gatorledger.
Explore more articles in the Research Reports category
